Zhao Mo, Li Tuowei, Cheng Cuicui, Mei Jun, Xu Fengqin, Li Yuanbai, Yang Yang, Yang Limin, Li Jing, Zhang Xiaojie, Liu Fangzhou, Jia Zhenhua, Hong Meng
Beijing University of Chinese Medicine, Beijing, China.
School of Food Science and Engineering, South China University of Technology, Guangzhou, China.
J Cosmet Dermatol. 2025 Jul;24(7):e70280. doi: 10.1111/jocd.70280.
This study aims to explore the mechanism of Bazi Bushen Capsule (BZBS) in treating skin laxity by combining network pharmacology and clinical research.
The active ingredients and potential drug targets of BZBS were obtained from TCMSP, TCMBANK, and SuperTCM databases. The potential disease targets of skin laxity were obtained from GeneCards, OMIM, and DisGeNET databases. The common core targets and key compounds were determined using Cytoscape software to construct the Drug Key Compound-Target network and Protein-Protein Interaction network. The mechanism of BZBS in treating skin laxity was revealed by Gene Ontology and KEGG enrichment analysis. Subsequently, to further verify the analysis results, a prospective single-group clinical trial was conducted, including 35 female volunteers with skin laxity. The planned study visits were initially scheduled for a 12-week period. The volunteers' average depth of skin wrinkles, skin elasticity parameters, and skin moisture content were examined at 0 week before the experiment and 12 weeks after the experiment.
Network pharmacology shows that key compounds are quercetin, kaempferol, arachidonate, suchilactone, ammidin, deoxyharringtonine, sitosterol, mandenol, ethyl linolenate, stigmasterol, poriferast-5-en-3beta-ol, and cholesterol; core targets include AKT1, IL6, TP53, TNF, EGFR, TGFB1, JUN, MMP9, MTOR, and MMP2; the Relaxin, MAPK, PI3K-Akt, JAK-STAT signaling pathways, and cellular senescence may be the main ways for BZBS in treating skin laxity. After BZBS treatment, the average wrinkling depth of the enrolled volunteers decreased, and the skin elasticity and moisture content increased.
BZBS may treat skin laxity by repairing the mucosal barrier, regulating protein metabolism, and showing good therapeutic effects.
WHO-recognized clinical trial registry: ChiCTR2200058262.
本研究旨在通过网络药理学与临床研究相结合的方法，探索八子补肾胶囊（BZBS）治疗皮肤松弛的机制。
从中药系统药理学数据库（TCMSP）、中药综合数据库（TCMBANK）和超级中药数据库获取BZBS的活性成分和潜在药物靶点。从基因卡片数据库（GeneCards）、在线人类孟德尔遗传数据库（OMIM）和疾病基因数据库（DisGeNET）获取皮肤松弛的潜在疾病靶点。使用Cytoscape软件确定共同的核心靶点和关键化合物，构建药物-关键化合物-靶点网络和蛋白质-蛋白质相互作用网络。通过基因本体论（Gene Ontology）和京都基因与基因组百科全书（KEGG）富集分析揭示BZBS治疗皮肤松弛的机制。随后，为进一步验证分析结果，进行了一项前瞻性单组临床试验，纳入35名皮肤松弛的女性志愿者。计划的研究访视最初安排为期12周。在实验前0周和实验后12周检查志愿者的皮肤皱纹平均深度、皮肤弹性参数和皮肤水分含量。
网络药理学显示，关键化合物有槲皮素、山奈酚、花生四烯酸盐、苏奇内酯、氨咪啶、去氧长春花碱、甾醇、曼德诺醇、亚麻酸乙酯、豆甾醇、海绵甾-5-烯-3β-醇和胆固醇；核心靶点包括AKT1、IL6、TP53、TNF、EGFR、TGFB1、JUN、MMP9、MTOR和MMP2；松弛素、丝裂原活化蛋白激酶（MAPK）、磷脂酰肌醇-3激酶-蛋白激酶B（PI3K-Akt）、Janus激酶-信号转导及转录激活因子（JAK-STAT）信号通路以及细胞衰老可能是BZBS治疗皮肤松弛的主要途径。BZBS治疗后，纳入的志愿者皮肤皱纹平均深度降低，皮肤弹性和水分含量增加。
BZBS可能通过修复黏膜屏障、调节蛋白质代谢来治疗皮肤松弛，并显示出良好的治疗效果。
世界卫生组织认可的临床试验注册库：中国临床试验注册中心（ChiCTR）注册号：ChiCTR2200058262 。
